Ghassan Abou-Alfa, MD

home / authors / ghassan-abou-alfa-md

Articles

Exploring Tislelizumab for Unresectable HCC

August 4th 2022

Ghassan K. Abou-Alfa, MD,discusses the phase 2 study of tislelizumab in patients with unresectable hepatocellular carcinoma.

Utilizing Tislelizumab to Treat Unresectable Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD

August 13th 2021

Ghasson K. Abou-Alfa, MD, discusses that phase 2 study of tislelizumab as treatment of patients with unresectable hepatocellular carcinoma.

Current Agents Approved for Treatment of HCC

Ghassan Abou-Alfa, MD

November 15th 2018

Ghassan Abou-Alfa, MD, discusses the approved agents available for the treatment of hepatocellular carcinoma. Compared to 2007 when there was only 1 agent available, sorafenib, there is now a great number of options for these patients.

The Role of Locoregional Therapy in the Treatment of Liver Cancer

Ghassan Abou-Alfa, MD

July 7th 2016

Ghassan Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering, discusses the important role that locoregional therapy plays in the treatment of liver cancer.

Dr. Ghassan Abou-Alfa on Possible Second-Line Treatments for HCC Patients

Ghassan Abou-Alfa, MD

November 11th 2015

Ghassan Abou-Alfa says serafnib is currently the only first-line treatment approved for HCC based on the SHARP trial, where the treatment showed improved survival in patients from 7.9 months to 10.7 months.